Arthromil™ - Clinical Trials
|I Product Info||I Ingredients||I Recommended Use||I Clinical Trials||I Research Brief||I References|
Indication: impaired joint mobility, weakened immunity, increased physical activity.
Main Actions: increases joint flexibility, promotes healthy cholesterol, strengthens the immune system, helps to maintain good intestinal health.
Ingredients (per 1 tablet): MicroLactin™ (Milk Protein Concentrate) – 500 mg, calcium – 143.5 mg.
Order this item
Low USA domestic & international
Arthromil™ - Clinical Trials:
The Effects of Milk Protein Concentrate on the Symptoms of Osteoarthritis in Adults: An Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial
John L Zenk, MD, Tami R Helmer, MD, and Michael A Kuskowski, PhD
Background: Reconstituted hyperimmune milk product has been shown to have anti-inflammatory qualities, prompting further research into its use for the relief of osteoarthritis symptoms. A concentrated form of this milk product, milk protein concentrate (MPC), contains the high-molecular-weight and low-molecular-weight components present in the reconstituted milk product.
Objective: The purpose of this exploratory study was to assess the effects of MPC on the symptoms of osteoarthritis in adults.
Methods: Patients aged > 19 years with physician-diagnosed osteoarthritis with daily joint pain, stiffness, and immobility were eligible. This was a prospective, randomized, double-blind, placebo-controlled trial lasting 6 weeks and having 3 treatment arms: MPC 2000 mg BID, glucosamine sulfate 500 mg TID, and placebo. Osteoarthritis symptoms were assessed using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index.
Results: Forty-two participants were enrolled (8 men, 34 women; mean age 59 years [range 34-86 years]); 35 patients (5 men, 30 women) completed the study. Due to significant baseline differences in 3 (stiffness, activities, and total) of the 4 (pain, stiffness, activities, and total) WOMAC Osteoarthritis Index scores in the placebo group compared with the MPC- and glucosamine sulfate-treated groups (P < 0.05), the results of this study were restricted to the analysis of intragroup performance from baseline to the completion of the study. The results showed significant improvement from baseline to week 6 for the MPC-treated group for all 4 scores (P < 0.005). In the glucosamine sulfate-treated group, a significant improvement was found in stiffness and total WOMAC Osteoarthritis Index scores from baseline to week 6 (P < 0.05 for both) but not in the pain or activities scores. In the placebo group, no significant changes were found in any of the WOMAC Osteoarthritis Index scores.
Conclusion: The results of this study indicate that MPC, when given at a dose of 2000 mg BID, was effective in relieving the symptoms of osteoarthritis, including joint pain, joint stiffness, and immobility, in this patient population1.
As principal investigator, Dr. Zenk recently conducted a double-blind clinical study to evaluate the effectiveness of MicroLactin™ for joint health. The results of the study reveal that MicroLactin™, when given in a dose of 2 grams twice daily, resulted in significant improvement in joint pain, stiffness, and activities of daily living.
In addition, MicroLactin™ was shown to be 33% better in relieving joint pain from daily activity when compared to Glucosamine. Due to its unique mechanism of action, Dr. Zenk believes that other joint support supplements, such as Glucosamine and Chondroitin, may work even better when taken with MicroLactin™. (1)
Cholesterol-Lowering Effect of Skim Milk from Immunized Cows in Hypercholesterolemic Patients
Alain Golay, Jean-Marc Ferrara, Jean-Pierre Felber, and Heinz Schneider
The effect of skim milk from cows immunized against a variety of human intestinal bacteria on serum cholesterol concentrations was examined in 11 patients with primary hypercholesterolemia in a 24 week, randomized, double-blind, placebo-controlled, crossover study. After a 4 week baseline period patients were treated for eight weeks either with skim milk from immunized cows (active) or with control skim milk (placebo) followed by an 8 week period with the treatment order reversed. Eight weeks of active treatment with skim milk from immunized cows reduced serum total cholesterol concentrations by 0.52-0.59 mmol/L (mean-SD: P<0.025), or 8%, LDL cholesterol by 0.16-0.59 mmol/L (NS), or 4% and the atherogenic index (total cholesterol/HDL cholesterol) by 0.42-1.85 (P<0.05), or 8%, compared with the placebo treatment. Reversal of the favorable development occurred upon cessation of active treatment. We conclude that daily supplementation of a normal diet with skim milk from immunized cows can result in a significant reduction of elevated blood cholesterol concentrations. (2)
Susan J Sharpe, Gregory D Gumble, and D Norman Sharpe
The plasma cholesterol-lowering and blood pressure effects of a skim milk powder (immune milk) produced from diary cows hyperimmunized with a multivalent bacterial vaccine were assessed in a double-blind crossover study of hypercholesterolemic subjects who consumed daily 90 g immune milk or a normal product. There was a significant reduction in plasma total and LDL cholesterol of 5.2% (95% CI 2.5, 7.9) and 7.4% (95% CI 4.1, 10.7), respectively, with 10 weeks of immune consumption compared with control, but no change in HDL cholesterol or triglycerides. A significant systolic and diastolic blood pressure-lowering effect (5 and 4 mm Hg, respectively) was also demonstrated. Thus, immune milk may be a useful adjunct in the dietary management of hypercholesterolemia and the mechanisms of its cholesterol-lowering and blood pressure effects warrant further study. (3)
A Multicenter, Double-blind, Placebo-controlled Study of Stolle Milk as Adjunct Therapy in Adult Rheumatoid Arthritis
Investigators included fourteen board-certified rheumatologists throughout U.S.A. The study was designed, monitored, and reported by Pharmaco, an Independent clinical research organization based in Austin, Texas; 1993
The study was designed to evaluate the safety and efficacy of Stolle milk powder compared with commercial (placebo) milk powder in 211 patients with adult rheumatoid arthritis. The dosage was 45 grams Stolle or control milk powder twice daily. Evaluation criteria included assessment of overall disease severity, joint counts, disability monitoring, duration of morning stiffness, consumption of arthritis medication, laboratory tests, and visual analog pain assessments.
Marked improvement was detected in Stolle milk patients with regard to joint counts, duration of morning stiffness, and visual analog pain scores.
Regarding side effects, no difference between Stolle milk and placebo groups and no clinically significant changes in laboratory test results or physical examinations were detected.